Initiator Pharma A/S
STO:INIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Initiator Pharma A/S
Additional Paid In Capital
Initiator Pharma A/S
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Initiator Pharma A/S
STO:INIT
|
Additional Paid In Capital
kr7.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Additional Paid In Capital
kr1.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Additional Paid In Capital
kr14.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
34%
|
CAGR 10-Years
28%
|
|
|
Galecto Inc
NASDAQ:GLTO
|
Additional Paid In Capital
$291.9m
|
CAGR 3-Years
2%
|
CAGR 5-Years
225%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Initiator Pharma A/S
Glance View
Initiator Pharma A/S is a clinical-stage biotechnology company, which engages in the development of novel therapeutics within the field of mono-amine reuptake transporters targeting central nervous system (CNS)-disorders. The firm focuses on developing drugs for treatment of erectile dysfunction.
See Also
What is Initiator Pharma A/S's Additional Paid In Capital?
Additional Paid In Capital
5.9m
DKK
Based on the financial report for Dec 31, 2024, Initiator Pharma A/S's Additional Paid In Capital amounts to 5.9m DKK.
What is Initiator Pharma A/S's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
19%
Over the last year, the Additional Paid In Capital growth was 7%. The average annual Additional Paid In Capital growth rates for Initiator Pharma A/S have been 9% over the past three years , 19% over the past five years .
